NYSE · ANVS
Healthcare · Biotechnology
$1.22
Down-$0.08 (-6.15%)
Updated Sep 10, 2026, 1:00 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ANVS closed at $1.22 after 20 trading sessions, down 32.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.31 | $1.32 | $1.22 | $1.22 | 1.75M |
| Sep 8, 2026 | $1.39 | $1.3981 | $1.30 | $1.30 | 1.96M |
| Sep 4, 2026 | $1.40 | $1.44 | $1.375 | $1.39 | 1.53M |
| Sep 3, 2026 | $1.65 | $1.6849 | $1.32 | $1.38 | 7.33M |
| Sep 2, 2026 | $1.71 | $1.759 | $1.69 | $1.70 | 606.83K |
| Sep 1, 2026 | $1.73 | $1.73 | $1.67 | $1.69 | 457.63K |
| Aug 31, 2026 | $1.72 | $1.7845 | $1.70 | $1.72 | 425.51K |
| Aug 28, 2026 | $1.78 | $1.83 | $1.71 | $1.72 | 504.51K |
| Aug 27, 2026 | $1.76 | $1.81 | $1.76 | $1.81 | 301.97K |
| Aug 26, 2026 | $1.84 | $1.8557 | $1.76 | $1.78 | 235.71K |
| Aug 25, 2026 | $1.76 | $1.825 | $1.76 | $1.82 | 560.28K |
| Aug 24, 2026 | $1.83 | $1.83 | $1.74 | $1.75 | 670.72K |
| Aug 21, 2026 | $1.78 | $1.8399 | $1.77 | $1.82 | 618.56K |
| Aug 20, 2026 | $1.84 | $1.89 | $1.78 | $1.79 | 548.82K |
| Aug 19, 2026 | $1.90 | $1.90 | $1.79 | $1.85 | 746.91K |
| Aug 18, 2026 | $1.75 | $1.82 | $1.74 | $1.80 | 449.5K |
| Aug 17, 2026 | $1.82 | $1.85 | $1.74 | $1.74 | 661.97K |
| Aug 14, 2026 | $1.83 | $1.90 | $1.80 | $1.85 | 949.71K |
| Aug 13, 2026 | $1.84 | $1.86 | $1.75 | $1.79 | 712.43K |
| Aug 12, 2026 | $1.87 | $1.8962 | $1.80 | $1.80 | 502.31K |
The latest Smart Investors Daily articles mentioning ANVS.
ANVS research
Company profile and research snapshot.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Roth Capital | Buy | — |
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 8, 2026 | Roth Capital | Buy | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Sep 30, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 13, 2026
MALVERN, Pa. - Annovis Bio, Inc. , a Phase 3 clinical - stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease...
Benzinga · Apr 10, 2026
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Fintel · Apr 9, 2026
Benzinga · Apr 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANVS.
